Review in Expert review of anti-infective therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
4 authors at 3 institutions in 2 countries.
Maxwell T Chirehwaa Division of Clinical Pharmacology, Department of Medicine , University of Cape Town , Rondebosch , South Africa.ORCID 0000-0002-1685-4882
Gustavo E Velásquezb Division of Infectious Diseases, Department of Medicine , Brigham and Women's Hospital , Boston , MA , USA.ORCID 0000-0003-1438-0692
Tawanda Gumbod Center for Infectious Diseases Research and Experimental Therapeutics , Baylor Research Institute, Baylor University Medical Center , Dallas , TX , USA.
Helen McIllerona Division of Clinical Pharmacology, Department of Medicine , University of Cape Town , Rondebosch , South Africa.
University of Cape Town · ZABaylor University Medical Center · USBrigham and Women's Hospital · US
Funding
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4M
Pharmacometric optimization of second line drugs for MDR tuberculosis treatmentR01AI116155 · NIAID · UNIVERSITY OF CAPE TOWN · PI GUMBO, TAWANDA, MCILLERON, HELEN · 2015 to 2019
$1.7M
Safety and tolerability of new and repurposed drugs for MDR-TB treatmentK08AI141740 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VELASQUEZ, GUSTAVO EDUARDO · 2019 to 2023
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Quantitative assessment of the activity of antituberculosis drugs and regimens. · full record | OpenQuestion